Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey
DOI:
https://doi.org/10.7175/fe.v15i2.924Keywords:
COPD, Cost-effectiveness, TiotropiumAbstract
BACKGROUND: Tiotropium monotherapy enables a significant minimization of morbidity in COPD. OBJECTIVE: to evaluate and compare cost and cost‑effectiveness of tiotropium monotherapy administrated for 24 months (18 μg od) in mild‑to‑moderate and severe chronic obstructive pulmonary disease (COPD). METHODS: Clinical outcomes (days in hospital; visits in general ward; cycles of systemic steroids; cycles of antibiotics and maintenance therapy drugs) were evaluated in two groups of patients corresponding to predicted FEV1 baseline values ≤ 50% (A) and > 50% (B) from the Italian NHS perspective. In order to perform cost‑effectiveness analysis, FEV1 value, available for each patient, was converted in SGRQ score using a published multivariate linear model. Utilities were then obtained through the Ståhl equation. RESULTS: The comparison between 24 months of standard therapy and subsequent 24‑month period of tiotropium monotherapy showed that hospitalization cost, which represents the driving treatment cost, drops from 77% to 69% (A) and from 67% to 33% (B) of the total cost. Differently, maintenance therapy cost increased but the amount was more than offset by the savings accruing from the shortening of hospitalization. Furthermore, cost‑effectiveness results revealed a mean savings of about 216 € (A) and 961 € (B) other than a mean gain of 0.07 QALY (A) and 0.02 QALY (B). Dominance of tiotropium (calculated only within patients completing treatment course) revealed that in almost 29% (A) and 36% (B) of subjects tiotropium strategy is dominant while only in 2% (A) and 7% (B) of cases is associated to costs increment and worsening on quality of life. The dominance was systematic in severe COPD. Statistical analyses confirm such trend. CONCLUSIONS: Results of the present study suggest that tiotropium used as unique treatment in COPD systematically consents significant costs savings together with positive effects on evaluated quality. These effects prove proportional to COPD severity.
References
Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-65; http://dx.doi.org/10.1164/rccm.201204-0596PP
Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117(suppl.2): 5-9s; http://dx.doi.org/10.1378/chest.117.2_suppl.5S
Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 188-207; http://dx.doi.org/10.1183/09031936.06.00024505
Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54; http://dx.doi.org/10.1056/NEJMoa0805800
Reilly JJ. COPD and declining FEV1 - Time to divide and conquer ? N Engl J Med 2008; 359: 1616-8; http://dx.doi.org/10.1056/NEJMe0807387
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-38; http://dx.doi.org/10.1164/rccm.200712-1869OC
Decramer M, Celli B, Kesten S, et al., for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecifi ed subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-8; http://dx.doi.org/10.1016/S0140-6736(09)61298-8
Jenkins CR, Jones PW, Calverly PMA, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009, 10: 59; http://dx.doi.org/10.1186/1465-9921-10-59
Tashkin DP, Celli B, Senn S, et al.; UPLIFT Study Investigators. A four-year trial of Thiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54; http://dx.doi.org/10.1056/NEJMoa0805800
Dal Negro RW, Bonadiman L, Micheletto C, et al. Changes of clinical outcomes and health care resources in moderate and in severe COPD treated uniquely with tiotropium 18 μg ad for twenty-four months. Pulm Pharmacol Ther 2011; 24: 373-6; http://dx.doi.org/10.1016/j.pupt.2011.03.004
National DRG tariff, 2009
Garattini L, Castelnuovo E, Lanzeni D, et al. Durata e costo delle visite in medicina generale: il progetto DYSCO. Farmeconomia e percorsi terapeutici 2003; 4: 109-114
Eurostat. Harmonized Indices of Consumer Prices (HICPs) Health sector referred. Available at http://epp.eurostat.ec.europa.eu/portal/page/portal/hicp/data/database
Informatore Farmaceutico, January 2014
Berry CE, Drummond MB, Han MK, et al. Relationship between SGRQ score and lung function differs by diagnosis. Am J Respir Crit Care Med 181; 2010: A5428
Ståhl E, Lindberg A, Jansson S, et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 2005; 3: 56
Nixon RM, Wonderling D, Grieve R. How to estimate cost-effectiveness acceptability curves, confidence ellipses and incremental net benefits alongside randomised controlled trials. Health Econ 2010; 19: 316-33; http://dx.doi.org/10.1002/hec.1477
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
